The global plasma fractionation market is witnessing robust expansion, driven by the growing demand for plasma-derived medicinal products that play a vital role in treating rare and life-threatening diseases. According to Expert Market Research, the market reached a value of USD 27.96 billion in 2024 and is expected to grow at a CAGR of 6.70% during the forecast period of 2025–2034 to reach approximately USD 53.48 billion by 2034. This growth is underpinned by an increase in chronic disease prevalence, improved diagnostics, and technological advancements in fractionation techniques.

Plasma Fractionation Market Share

The plasma fractionation market is dominated by North America, accounting for the largest revenue share, thanks to its advanced healthcare infrastructure, high demand for immunoglobulins, and favorable reimbursement policies. Europe follows closely, driven by regulatory support and awareness initiatives for plasma-derived therapies. Asia Pacific is expected to witness the fastest growth due to rising healthcare expenditure, large patient pools, and increasing adoption of advanced blood plasma therapies.

In terms of products, immunoglobulins hold the largest share, attributed to their widespread application in treating immune deficiencies and neurological disorders. Coagulation factor concentrates, especially Factor VIII and IX, also command a significant portion due to their critical role in hemophilia treatment.

Plasma Fractionation Market Growth & Trends

The plasma fractionation market is experiencing several key growth drivers and emerging trends:

  • Rising prevalence of rare and chronic diseases such as primary immunodeficiency diseases, hemophilia, and autoimmune disorders is accelerating demand for plasma-derived therapies.

  • Technological advancements in chromatographic separation and virus inactivation techniques have significantly improved product purity and safety.

  • Growth in elderly populations, especially in developed nations, is contributing to increased plasma collection and usage due to higher susceptibility to immune-related conditions.

  • Expansion of blood donation programs and awareness campaigns in emerging economies is also playing a role in boosting plasma supply.

Notably, recombinant alternatives are becoming more prominent but are not expected to displace plasma-derived products entirely due to their unique advantages in certain clinical cases.

Plasma Fractionation Market Case Studies & News

Recent industry developments highlight the dynamic nature of the plasma fractionation sector:

  • In 2023, Takeda Pharmaceutical expanded its plasma collection capacity by opening several new plasma centers in the U.S. and Europe, aiming to meet growing global demand.

  • Grifols, a leading player, launched its state-of-the-art fractionation plant in Canada, expected to process millions of liters of plasma annually.

  • In 2022, CSL Behring announced a partnership with South Korea's GC Pharma to co-develop immunoglobulin products, leveraging regional synergies.

  • According to Wikipedia, plasma protein fractions are increasingly used in various therapies including treatment for burns, shock, and liver disease.

These cases exemplify how companies are strategically investing in both capacity expansion and global partnerships to strengthen their market positions.

Plasma Fractionation Market Analysis

The market is characterized by high entry barriers, owing to complex manufacturing processes, stringent regulatory frameworks, and high capital investment. The competitive landscape is relatively consolidated, with a few large players controlling significant market shares.

Regulatory dynamics in major regions such as the U.S. FDA, European Medicines Agency (EMA), and PMDA Japan have also played a crucial role in shaping market strategies and product approvals. Companies that align with evolving compliance standards and invest in R&D are poised to benefit the most.

Plasma Fractionation Market Segmentation

A detailed segmentation of the market reveals the depth of its applications and processes:

By Product

  • Immunoglobulins (dominant segment due to demand in immunology and neurology)

  • Coagulation Factor Concentrates (critical for hematology and hemophilia)

  • Albumin

  • Protease Inhibitors

  • Others

By Method

  • Centrifugation

  • Depth Filtration

  • Chromatography (gaining popularity due to higher purity yields)

  • Others

By Application

  • Neurology

  • Hematology

  • Oncology

  • Immunology

  • Pulmonology

  • Others

By End User

  • Hospitals and Clinics

  • Clinical Research Laboratories

  • Academic Institutes

  • Others

By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

Each region presents distinct opportunities and challenges, with Asia Pacific expected to become a high-growth zone due to infrastructure investments and increasing patient awareness.

Plasma Fractionation Market Key Players

Leading companies in the plasma fractionation market are strategically focusing on mergers, facility expansions, and product innovation:

  • CSL Plasma LLC

  • Grifols, S.A.

  • Takeda Pharmaceutical Company Limited

  • Biotest Group

  • Baxter International Inc.

  • OCTAPHARMA AG

  • KEDRION S.P.A

  • LFB S.A.

  • BIOTEST AG

  • SANQUIN

  • BIO PRODUCTS LABORATORY LTD.

  • INTAS PHARMACEUTICALS LTD.

  • GC Pharma

  • Emergent Biosolutions

  • Japan Blood Products Organisation

These players dominate global supply chains, and their integrated operations from plasma collection to fractionation and distribution give them a competitive edge.

The plasma fractionation market is poised for sustained growth, driven by medical needs, biotechnological innovations, and expanding healthcare coverage across the globe. As research deepens and therapies evolve, the market will continue to play a pivotal role in advancing treatment for complex and chronic health conditions.

For more in-depth analysis, insights, and future forecasts, refer to the comprehensive reports available from Expert Market Research.

Find More Report:

CDMO Market trend

Treatment Resistant Depression Drug Pipeline Analysis growth

Metastatic Castration-Resistant Prostate Cancer Drug Pipeline Analysis share